Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma

Código QR

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma

Abstract Aim To investigate the therapeutic effect of lenvatinib (LEN) in liver disease etiology, especially nonviral hepatocellular carcinoma (HCC). Methods and Results Sixty‐seven patients with unresectable advanced HCC (u‐HCC) treated with LEN and consisting of 26 hepatitis C virus (HCV), 19 hepa...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tetsu Tomonari, Yasushi Sato, Hironori Tanaka, Takeshi Mitsuhashi, Akihiro Hirao, Takahiro Tanaka, Tatsuya Taniguchi, Koichi Okamoto, Masahiro Sogabe, Hiroshi Miyamoto, Naoki Muguruma, Tetsuji Takayama
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	atezolizumab bevacizumab lenvatinib Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/db021b52981d4cb7841a5b454ff3109b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Lenvatinib as the key component of first-line therapy for patients with unresectable hepatocellular carcinoma
por: L. V. Bolotina
Publicado: (2020)

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study
por: Qiyi Zhang, et al.
Publicado: (2021)

Pneumatosis intestinalis associated with lenvatinib during thyroid cancer treatment: a case report
por: Soji Toda, et al.
Publicado: (2021)

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
por: Skubalova Z, et al.
Publicado: (2021)

The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib
por: Katarína Vavrová, et al.
Publicado: (2022)

Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy
por: Masatoshi Kudo
Publicado: (2021)

Treatment of metastatic hepatocellular carcinoma with lenvatinib. Case report and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)

The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma
por: Jie Zhu, et al.
Publicado: (2021)

Lenvatinib Plus Immune Checkpoint Inhibitors Improve Survival in Advanced Hepatocellular Carcinoma: A Retrospective Study
por: Xiaozhun Huang, et al.
Publicado: (2021)

A Novel Treatment Strategy for Patients with Intermediate-Stage HCC Who Are Not Suitable for TACE: Upfront Systemic Therapy Followed by Curative Conversion
por: Masatoshi Kudo
Publicado: (2021)

Long-Term Survival due to Chemotherapy including Paclitaxel in a Patient with Metastatic Primary Splenic Angiosarcoma
por: Masanori Takehara, et al.
Publicado: (2021)

Revealing the suppressive role of protein kinase C delta and p38 mitogen-activated protein kinase (MAPK)/NF-κB axis associates with lenvatinib-inhibited progression in hepatocellular carcinoma in vitro and in vivo
por: Ching-Hsuan Wu, et al.
Publicado: (2022)

Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
por: Yusuke Johira, et al.
Publicado: (2021)

Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study
por: Atsushi Hiraoka, et al.
Publicado: (2021)

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
por: Mina LA, et al.
Publicado: (2020)

New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
por: Seetharamu N, et al.
Publicado: (2017)

Treatment of advanced small cell lung cancer. Clinical case and literature review
por: Konstantin V. Menshikov, et al.
Publicado: (2021)

Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
por: Anne Christine Kaae, et al.
Publicado: (2021)

Opportunities for metastatic triple negative breast cancer therapy
por: Inna P. Ganshina, et al.
Publicado: (2021)

Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity
por: Obata S, et al.
Publicado: (2019)

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer
por: Di Bartolomeo M, et al.
Publicado: (2015)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
por: Kiss S, et al.
Publicado: (2018)

Retinopatía del prematuro: Actualización en detección y tratamiento
por: Bancalari M.,Aldo, et al.
Publicado: (2020)

Glaucoma drainage device implantation with adjunctive intravitreal bevacizumab in neovascular glaucoma: 3-year experience
por: Noor NA, et al.
Publicado: (2017)

Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab
por: Shakarchi FI, et al.
Publicado: (2018)

Tratamiento de la retinopatía del prematuro con bevacizumab intravítreo
por: BANCALARI M,ALDO, et al.
Publicado: (2013)

Differences in Several Factors in the Development of Erosive Esophagitis Among Patients at Various Stages of Metabolic Syndrome: A Cross-Sectional Study
por: Sogabe M, et al.
Publicado: (2021)

Disease control with prior platinum-based chemotherapy is prognostic for survival in patients with metastatic urothelial cancer treated with atezolizumab in real-world practice
por: Mencinger Marina, et al.
Publicado: (2021)

Short-Term Outcomes After COVID-19-Related Treatment Interruption Among Patients with Neovascular Age-Related Macular Degeneration Receiving Intravitreal Bevacizumab
por: Allegrini D, et al.
Publicado: (2021)

Effects of Intravitreal Bevacizumab Therapy in Patients with Proliferative Diabetic Retinopathy
por: Ribeiro de Carvalho G, et al.
Publicado: (2020)

The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
por: Haiyan Jia, et al.
Publicado: (2021)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
por: Liu J, et al.
Publicado: (2019)

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
por: Pessoa B, et al.
Publicado: (2021)

Evaluation Of The Timing Of Intravitreal Bevacizumab Injection As Adjuvant Therapy To Panretinal Photocoagulation In Patients With Diabetic Macular Edema Secondary To Diabetic Retinopathy
por: Kartasasmita A, et al.
Publicado: (2019)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
por: Lin CJ, et al.
Publicado: (2016)

Immediate sequential bilateral intravitreal injections: an Indian perspective
por: Tripathy K
Publicado: (2017)

Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
por: Majid Abrishami, et al.
Publicado: (2021)

Targeted nonviral gene therapy in prostate cancer
por: Altwaijry N, et al.
Publicado: (2018)

The outcome of low-frequency intravitreal bevacizumab therapy for macular edema in retinal vein occlusions
por: Ivanovska Adjievska B, et al.
Publicado: (2017)

Efficacy and Safety of Different Doses of Bevacizumab Combined With Pemetrexed and Platinum in First-Line Treatment of Advanced NSCLC: A Retrospective-Real World Study
por: Chun-Hua Zhou, et al.
Publicado: (2021)